UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (date of earliest event reported):
February 5, 2017
OWC
PHARMACEUTICAL RESEARCH CORP.
(Exact Name of
Registrant as Specified in its Charter)
Commission File No.: 0-54856
|
Delaware
|
98-0573566
|
|
(State of Incorporation)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
30 Shacham Street. P.O.B.
8324 Petach Tikva, Israel
|
4918103
|
|
(Address of Principal Executive Offices)
|
(ZIP Code)
|
Registrant's
Telephone Number, including area code: 972 (0) 3-758-2657
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On February 5, 2017, OWC Pharmaceutical Research Corp.
(the "Registrant") appointed Dr. Sharon Rozenblat as a Senior Advisor to the
Scientific Advisory Board of the Registrant's wholly-owned Israeli
subsidiary, One World Cannabis Ltd ("OWC Israel"). In her capacity as Senior
advisor, Dr. Rozenblat will oversee, supervise and bring to fruition the
commercial application of OWC Israel's cannabinoid-based medical skin
treatment, as she leads the completion of the study of psoriasis, which
commenced in November 2016.
Dr. Rozenblat has served as an independent consultant to
companied engaged in the field of research and development, principally
involving herbal products for the pharmaceutical and raw materials
industries. Dr. Rozenblat has also assisted companies in the convergence of
science and the commercial exploitation of innovative products based on
botanicals.
Dr. Rozenblat has over 15 years of experience in
research and development of the study and application of herbal extracts for
medical products mainly in the field of dermatology. From 2007 through 2015,
Dr. Rozenblat served as the Chief Scientist at Kamedis Ltd., located in Tel
Aviv-Yafo, Israel, an herbal-based dermatological company that was founded
in 1998 for development of products to treat skin conditions. As the Chief
Scientist, Dr. Rozenblat was also Director of Kamedis' R&D Department,
integrating traditional herbal knowledge with advanced pharmacology for the
development of herbal-based products for the treatment of a variety of human
dermatological conditions.
Prior to her position at Kamedis, Dr. Rozenblat served as
Scientific Research Director of joint development projects funded by the
Korea-Israel Industrial R&D Foundation (KORIL) and Israel-Singapore
foundation (SIIRD) which resulted in numerous products and patents. Dr.
Rozenblat was also the Scientific Director for the development of herbal
extraction in an herbal production JV in Chengdu, China, during which she
was involved in uncovering and utilizing agricultural elements and
developing extraction techniques to create commercial products for the
treatment of skin conditions.
Dr. Rozenblat received her PhD in biochemistry from Bar-Ilan
University, Ramat Gan, Israel in 2007, graduating Magna Cum Laude in the
field of "anti-cancer activity of Inula viscosa on melanoma (skin cancer)
cells."
|
|
OWC Pharmaceutical
Research Corp.
|
|
|
|
|
|
|
|
By:
|
/s/ Mordechai
Bignitz
|
|
|
Name:
|
Mordechai Bignitz
|
|
|
Title:
|
Chief Executive
Officer
|
Date: February 6, 2017